We're getting a lot of feedback and information from people who know a lot about health care. I got the post below as an email from a health care expert who I've known for years. The person told me I could publish it, but without attribution. Trust me, this person knows of what they speak.
The profit motive is powerful. And, the health care industry, including the insurance companies, sure know how to manipulate it:
Research conducted over the past 20 years has demonstrated unequivocally that standard pharmaceutical industry practices --- which include paying for meals, trips, conferences and courses for doctors, their office staff and families --- has a big influence on the prescribing habits of doctors, sometimes in ways that are not in patients’ best interests. Despite regular reform proposals from editors of influential medical journals and occasional media attention, little has changed in practice.
Obviously, this continues because both doctors and the pharmaceutical industry consider that the status quo is in their best financial interest. Doctors benefit from the gifts, meals and trips, while the pharmaceutical industry benefits from the added profits derived from expanded market share.
Which brings us to our legislators. The Washington Post today reported that members of Congress key to health reform, including Senate Finance Committee Chair Max Baucus, depend on contributions from the very industry that profits from our broken health care system. It seems that one in five dollars in campaign contributions Senator Baucus received between 2003 and 2008 came from the health care industry and its lobbyists, while just one in ten dollars came from contributors in his home state.
When confronted with research evidence showing how physicians’ interactions with the pharmaceutical sales force influence prescribing, doctors respond by insisting that they personally are not affected, even though they suspect the average doctor might be. We see the same kinds of responses from the politicians, who tell us that their own views are not biased by the relationships they develop with insurance and drug industry lobbyists at big-ticket fundraisers held in private settings.
It is hard not to suspect that the financial relationship between industry and Senator Baucus explains why a public plan option --- much less a single-payer approach--- has been taken off the agenda of the Senate Finance Committee, even though polls show nearly three quarters of Americans would like to see a public option included in reform. And even though they --- and we --- are in desperate need of a reform plan that would simultaneously rein in costs while expanding coverage.
One reason lawmakers can’t finalize a bill before the August recess is that there is no way to do what their patrons demand --- ensure robust industry profits --- while controlling costs and expanding to access to health care. An additional few weeks or few months of reflection will not change that basic fact, although it will buy time in which advocates of reform can find common ground, expand their ranks, and spread misinformation to sway public support.
Those who oppose campaign finance reform on free speech grounds don’t seem to appreciate that the concentrated interests of the few always outweigh the diffuse interests of the many. Unfortunately for all of us who would like to see meaningful reform enacted, it looks as though the powerful minority is poised to demonstrate that lesson for us once again.
